Publication
2024
- Halilovic, M. et al. 2024. Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.. Leukemia 38, pp. 2561-2572. (10.1038/s41375-024-02405-5)
2023
- Jonas, B. A. et al. 2023. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. Hematological Oncology 41(4), pp. 743-752. (10.1002/hon.3159)
- Dolton, G. et al. 2023. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell 186(16), pp. 3333-3349., article number: E27. (10.1016/j.cell.2023.06.020)
2022
- Chiriches, C. et al. 2022. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation. PLoS Genetics 18(10), article number: e1010463. (10.1371/journal.pgen.1010463)
2020
- Zabkiewicz, J. et al. 2020. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia. British Journal of Haematology 191(2), pp. 231-242. (10.1111/bjh.16665)
Articles
- Halilovic, M. et al. 2024. Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.. Leukemia 38, pp. 2561-2572. (10.1038/s41375-024-02405-5)
- Jonas, B. A. et al. 2023. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. Hematological Oncology 41(4), pp. 743-752. (10.1002/hon.3159)
- Dolton, G. et al. 2023. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell 186(16), pp. 3333-3349., article number: E27. (10.1016/j.cell.2023.06.020)
- Chiriches, C. et al. 2022. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation. PLoS Genetics 18(10), article number: e1010463. (10.1371/journal.pgen.1010463)
- Zabkiewicz, J. et al. 2020. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia. British Journal of Haematology 191(2), pp. 231-242. (10.1111/bjh.16665)